Sandoz Group AG announced on Monday that it has reached two separate agreements totaling $478.5 million to settle long-standing antitrust litigation regarding generic-drug pricing in the United States.
Under the terms of the deals, the Swiss pharmaceuticals manufacturer will distribute the payments over a seven-year period starting in 2027. The vast majority of the sum, $450 million (CHF 388 million), will resolve litigation brought by U.S. states and territories. The remaining $28.5 million is allocated to settle a class-action suit filed by indirect resellers, which includes retail pharmacies, clinics, and hospital systems.
The core of the legal dispute centered on allegations that Sandoz engaged in unlawful price-fixing, market allocation, and bid-rigging within the U.S. generic medicine market. Sandoz continues to reject these allegations and maintained that neither agreement contains an admission of fault or liability.
According to the company, these resolutions effectively clear all claims brought by U.S. federal and state government authorities, as well as all remaining class actions tied to the overarching proceedings. The only unresolved legal matters connected to the generic pricing inquiry are individual claims from plaintiffs who previously opted out of earlier class-action settlements.
Some portions of the agreements still require formal judicial approval before becoming final. However, Sandoz clarified that the financial obligations stemming from the settlements will have no impact on its full-year 2026 business forecast or its broader medium-term financial outlook.